ReviewFrontiers in immunology2026
Regulatory complexity and therapeutic targeting of the necroptosis network.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Role of Traditional Chinese Medicine in Acute Lung Injury: Targeting Programmed Cell Death.Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Necroptosis, a regulated form of necrotic cell death governed by the RIPK1-RIPK3-MLKL axis, is critically involved in host defense, inflammatory responses, and the pathogenesis of diverse diseases. Given the expanding complexity of its signaling networks and their context-dependent outcomes, a synthesized overview is essential. This review aims to: (1) delineate both canonical and non-canonical pathways of necroptosis induction; (2) elucidate the multifaceted regulation of its core executors (RIPK1, RIPK3, MLKL) by post-translational modifications and epigenetic mechanisms; and (3) analyze the intricate crosstalk between necroptosis and other cellular processes, including apoptosis, autophagy, and metabolic pathways. The subsequent analysis will evaluate how this sophisticated regulatory architecture poses challenges while unveiling novel therapeutic vulnerabilities. Finally, emerging translational strategies that target necroptosis in inflammatory, neurodegenerative, and ischemic conditions are discussed, and propose future directions to bridge mechanistic discoveries to clinical applications. Notably, beyond its pathogenic roles, necroptosis also functions as an essential host defense mechanism against viral infection and represents a promising therapeutic strategy for eliminating apoptosis-resistant cancer cells, highlighting its context-dependent dual nature.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.